Renal Cell Carcinoma Phenotypes in Young Women: A Narrative Review of Epidemiologic, Histologic, Molecular and Clinical Evidence

Renal cell carcinoma (RCC) predominantly affects older men, and the phenotype of RCC arising in women younger than 45 years has not, to our knowledge, been characterized in a defined population. We conducted a narrative review of registry analyses, multi-institutional pathology series, germline-testing cohorts, consensus classifications and guidelines, and graded every finding by how directly it applies to young women. Registry data show that the male-to-female ratio narrows with decreasing age, from approximately 1.7:1 across all ages to near parity in pediatric and adolescent cohorts. In the only registry analysis with a sex-by-age subtype breakdown (Surveillance, Epidemiology, and End Results [SEER]-18, 2001–2008), chromophobe RCC accounted for 215 of 330 non-clear cell RCC cases (65.2%; 95% confidence interval 59.9–70.1%) in surgically treated women younger than 40 years, whereas papillary RCC led in every other sex-by-age group and among young Black women. In an exploratory reanalysis of the published counts, this pattern was explained by independent, multiplicative effects of female sex and young age on chromophobe histology, without evidence of a sex-by-age interaction among non-clear cell tumors; it rests on a single registry period with registry-coded histology and awaits validation. Clear cell RCC nevertheless remains the most common subtype in all strata. Entities with documented female predominance (chromophobe RCC, eosinophilic solid and cystic RCC, tuberous sclerosis-associated RCC, mucinous tubular and spindle cell carcinoma) and entities concentrated in the young (microphthalmia-associated transcription factor [MiT] family translocation RCC, succinate dehydrogenase [SDH]-deficient RCC, fumarate hydratase-deficient RCC, renal medullary carcinoma) together define a phenotype landscape that differs from that of older men. Most of this landscape, however, is inferred from mixed-sex young-onset cohorts, all-age sex-difference analyses, and entity-defining pathology series rather than from studies of women younger than 45 years. Early-onset RCC is enriched for hereditary syndromes, some of which present in women through uterine leiomyomas or lymphangioleiomyomatosis, and current American and European guidelines recommend genetic evaluation for patients diagnosed at 46 years or younger. Syndrome-directed therapies now exist for von Hippel–Lindau disease, hereditary leiomyomatosis and renal cell cancer, and tuberous sclerosis complex, but sex- and age-stratified treatment data are sparse. Evidence on hormonal and reproductive determinants is inconsistent, and sex-stratified data on early-onset germline burden and outcomes are lacking. We distinguish verified findings from hypotheses, flag common but unsupported claims, and outline the contemporary, population-based and molecularly classified cohorts needed to validate the proposed phenotype landscape.